二甲双胍在1型糖尿病患者中的心血管与代谢效应(REMOVAL):一项双盲、随机、安慰剂对照试验
REMOVAL试验在5国23个中心纳入40岁以上、1型糖尿病病程≥5年且合并至少3项心血管危险因素的成人,随机接受二甲双胍1000 mg每日两次或安慰剂。主要终点平均颈动脉内膜中层厚度进展未显著降低,但最大cIMT进展显著降低;HbA1c、体重、LDL胆固醇降低,eGFR升高,胰岛素需求未降低。
要点
- 二甲双胍未显著降低平均cIMT年进展(-0.005 mm/年,95%CI -0.012至0.002;p=0.1664)。
- 二甲双胍组最大cIMT年进展显著降低(-0.013 mm/年,95%CI -0.024至-0.003;p=0.0093)。
- 二甲双胍组体重和LDL胆固醇降低、eGFR升高,但胰岛素需求平均未降低。
核心结论
- 这些数据不支持当前指南所建议的使用二甲双胍改善长期1型糖尿病成人的血糖控制,但提示其可能在心血管风险管理中有更广泛的作用。
研究设计与样本
- REMOVAL为双盲、安慰剂对照试验,在5个国家(澳大利亚、加拿大、丹麦、荷兰、英国)的23个医院糖尿病门诊开展。
- 纳入40岁及以上、1型糖尿病病程至少5年、且具备10项特定心血管危险因素中至少3项的成人。
- 428例随机分配患者中,219例分入二甲双胍组(口服1000 mg每日两次),209例分入安慰剂组;主要终点为3年内每年量化的平均远壁cIMT,在改良意向治疗人群中用重复测量回归分析。
主要发现
- 平均cIMT进展未显著降低:二甲双胍组-0.005 mm/年(95%CI -0.012至0.002;p=0.1664)。
- 预设三级结局最大cIMT进展显著降低:二甲双胍组-0.013 mm/年(95%CI -0.024至-0.003;p=0.0093)。
- HbA1c在3年平均降低-0.13%(95%CI -0.22至-0.037;p=0.0060),但归因于3个月时点的降低(-0.24%,95%CI -0.34至-0.13;p<0.0001),此后未持续(访视×治疗交互p=0.0163)。
- 3年治疗中,二甲双胍组体重降低-1.17 kg(95%CI -1.66至-0.69;p<0.0001),LDL胆固醇降低-0.13 mmol/L(95%CI -0.24至-0.03;p=0.0117),eGFR升高4.0 mL/min per 1.73m2(95%CI 2.19至5.82;p<0.0001)。
- 胰岛素需求3年平均未降低(-0.005 units/kg,95%CI -0.022至0.012;p=0.545),但访视×治疗交互显著(p=0.0018);反应性充血指数评估的内皮功能或视网膜病变无效应。
临床怎么用
- 原文结论指出这些数据不支持当前指南所建议的使用二甲双胍改善长期1型糖尿病成人的血糖控制,但提示其可能在心血管风险管理中有更广泛的作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metformin might reduce insulin requirement and improve glycaemia in patients with type 1 diabetes, but whether it has cardiovascular benefits is unknown. We aimed to investigate whether metformin treatment (added to titrated insulin therapy) reduced atherosclerosis, as measured by progression of common carotid artery intima-media thickness (cIMT), in adults with type 1 diabetes at increased risk for cardiovascular disease. METHODS: REMOVAL was a double-blind, placebo-controlled trial undertaken at 23 hospital diabetes clinics in five countries (Australia, Canada, Denmark, the Netherlands, and the UK). Adults aged 40 years and older with type 1 diabetes of at least 5 years' duration and at least three of ten specific cardiovascular risk factors were randomly assigned (via an interactive voice response system) to oral metformin 1000 mg twice daily or placebo. Participants and site staff were masked to treatment allocation. The primary outcome was averaged mean far-wall cIMT, quantified annually for 3 years, analysed in a modified intention-to-treat population (all randomly assigned participants with post-randomisation data available for the outcome of interest at any given timepoint, irrespective of subsequent adherence or study participation), using repeated measures regression. Secondary outcomes were HbA1c, LDL cholesterol, estimated glomerular filtration rate (eGFR), incident microalbuminuria (not reported), incident retinopathy, bodyweight, insulin dose, and endothelial function, also analysed in all participants with post-randomisation data available for the outcome of interest at any given timepoint. This trial is registered with ClinicalTrials.gov, number NCT01483560. FINDINGS: Between Dec 14, 2011, and June 24, 2014, 493 participants entered a 3 month run-in to optimise risk factor and glycaemic control (single-blind placebo in the final month). Of 428 randomly assigned patients, 219 were allocated to metformin and 209 to placebo. Progression of mean cIMT was not significantly reduced with metformin (-0·005 mm per year, 95% CI -0·012 to 0·002; p=0·1664), although maximal cIMT (a prespecified tertiary outcome) was significantly reduced (-0·013 mm per year, -0·024 to -0·003; p=0·0093). HbA1c (mean 8·1% [SD 0·9] for metformin and 8·0% [0·8] for placebo at baseline) was reduced on average over 3 years by metformin (-0·13%, 95% CI -0·22 to -0·037; p=0·0060), but this was accounted for by a reduction at the 3-month timepoint (-0·24%, -0·34 to -0·13; p<0·0001) that was not sustained thereafter (p=0·0163 for visit-by-treatment interaction). Bodyweight (-1·17 kg, 95% CI -1·66 to -0·69; p<0·0001) and LDL cholesterol (-0·13 mmol/L, -0·24 to -0·03; p=0·0117) were reduced with metformin over 3 years of treatment, and eGFR was increased (4·0 mL/min per 1·73m2, 2·19 to 5·82; p<0·0001). Insulin requirement was not reduced on average over 3 years (-0·005 units per kg, 95% CI -0·022 to 0·012; p=0·545), but there was a significant visit-by-treatment interaction (p=0·0018). There was no effect on endothelial function as measured by reactive hyperaemia index, or on retinopathy. Discontinuation of treatment in 59 (27%) participants on metformin versus 26 (12%) on placebo (p=0·0002) was mainly due to an excess of gastrointestinal adverse effects, and there was no increase in hypoglycaemia with metformin. Five deaths occurred among patients allocated to metformin and two occurred among those allocated to placebo; none were judged by site principal investigators to be related to study medication. INTERPRETATION: These data do not support use of metformin to improve glycaemic control in adults with long-standing type 1 diabetes as suggested by current guidelines, but suggest that it might have a wider role in cardiovascular risk management. FUNDING: JDRF.
引用
- Petrie JR, Chaturvedi N, Ford I, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017. PMID: 28615149. doi:10.1016/S2213-8587(17)30194-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。